AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06788509 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: JNJ-67856633
Description: Participants from the parent studies (64264681LYM1002 \[NCT04657224\], 67856633LYM1002 \[NCT04876092\] and 67856633LYM1001 \[NCT03900598\]) who are deriving benefit from study treatment will continue to receive JNJ-67856633 orally.
Study NCT06788509 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: JNJ-54179060
Description: Participants from the parent study (67856633LYM1002 \[NCT04876092\]) who are deriving benefit from study treatment will continue to receive JNJ-54179060 orally.
Study NCT06788509 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: JNJ-64264681
Description: Participants from the parent studies (64264681LYM1001 \[NCT04210219\], 64264681LYM1002 \[NCT04657224\]) who are deriving benefit from study treatment will continue to receive JNJ-64264681 orally.
Study NCT06788509 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: JNJ-74856665
Description: Participants from the parent study (74856665AML1001 \[NCT04609826\]) who are deriving benefit from study treatment will continue to receive JNJ-74856665 orally.
Study NCT06788509 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: JNJ-70218902
Description: Participants from the parent study (70218902EDI1001 \[NCT04397276\]) who are deriving benefit from study treatment will continue to receive JNJ-70218902 orally.
Study NCT06788509 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: JNJ-64619178
Description: Participants from the parent study (64619178EDI1001 \[NCT03573310\]) who are deriving benefit from study treatment will continue to receive JNJ-64619178 orally.
Study NCT06789588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pharmacogenetic algorithm
Description: The dose predictor algorithm proposed in this work aims to maintain and quality treatment in an individualized and effective manner. In the routine use protocol, warfarin is prescribed based only on the INR collected within 5 days. The proposed intervention protocol is based on the patient's clinical and genetic factors, such as genetic polymorphisms, age, weight, height, race, use of amiodarone, statins, antifungals or antibiotics, tobacco use, clinical indication and what the RNI target.
Study NCT06789588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clinical treatment
Description: Patients with AF indicated for OAC therapy guided by institutional protocol.
Study NCT06788678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVED
Description: MOVED includes 8 self-guided, web-based sessions administered over 4 weeks. Web-based sessions include 3 core components: (1) elicit moral elevation, (2) engage in reflection about moral elevation response, and (3) set a behavioral goal that is inspired by the moral elevation exercise.
Study NCT06788678 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Care Control
Description: A present-centered, nondirective intervention that aims to control for the nonspecific therapeutic effects of supportive care. In this case, the effects of engaging in regular web-based sessions that convey information about PTSD symptoms. Sessions will include psychoeducation materials about PTSD symptoms, functioning, and resources for dealing with related stressors. Key components of MOVED will be strictly excluded.
Study NCT06788171 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy
Description: PULSAR (SBRT): A targeted radiation therapy delivering 5-10 Gy/fraction every 3 weeks (q3w) to the gross tumor volume (GTV), for 3 times.
Study NCT06788171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab: 5mg/kg, d1, q3w, 6 cycles.
Study NCT06788171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: 1000mg/m2, d1-14, bid, q3w, 6 cycles.
Study NCT06788171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin: 130mg/m2, d1, q3w, 6 cycles.
Study NCT06788171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab: 200mg, d1, q3w, 6 cycles.
Study NCT06789978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal cardiopulmonary resuscitation (ECPR)
Description: Prehospital extracorporeal cardiopulmonary resuscitation (ECPR)
Study NCT05583448 — intervention group
Intervention type: DEVICE
Intervention: ExploR Radial Head
Description: Patient must have undergone primary elbow arthroplasty with the ExploR Radial Head System according to a cleared indication.
Study NCT06789302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DT2-SCT intravenous infusion
Description: DT2-SCT is an investigational therapy using autologous adipose-derived mesenchymal stem cells (MSCs) prepared from each participant's adipose tissue. MSCs are isolated from approximately 50 mL of adipose tissue obtained through a tumescent liposuction procedure. The cells are expanded, tested for contaminants, and suspended in a sterile, cryopreservation-free medium (Plasma-Lyte A) for administration.~The intervention involves a single intravenous infusion of DT2-SCT at a dosage of 1 x 10\^6 MSCs/kg body weight, delivered over a period of one hour. Participants will be closely monitored for at least two hours post-infusion to assess immediate safety and potential adverse effects.
Study NCT06789302 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the placebo group (Group B) will receive a single intravenous infusion of Plasma-Lyte A, a sterile, isotonic, non-pyrogenic crystalloid solution. The infusion will be administered in a volume of 100 mL over a period of one hour.
Study NCT06785090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromfenac
Description: Bromfenac is a non-steroidal anti-inflammatory drug (NSAID) formulated as a 0.09% ophthalmic solution. It is administered to reduce inflammation and prevent cystoid macular edema (CME) following cataract surgery.
Study NCT06785090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5% ophthalmic solution
Description: antibiotic, standard postoperative care regimen
Study NCT06785090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 0.5% ophthalmic solution
Description: antibiotic, standard postoperative care regimen
Study NCT06577935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGA2118
Description: Subcutaneous injection
Study NCT05882734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M1774
Description: In Phase 1b, M1774 will be administered as dosing regimen 1 or dosing regimen 2 until disease progression, death discontinuation criteria or any other reason. The selected dosing regimen of M1774 will be administered in all arms of Phase 2a.
Study NCT05882734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab will be administered as an intravenous infusion every 3 weeks in all arms of Phase 1b and Phase 2a until disease progression, death discontinuation criteria or any other reason.
Study NCT05495243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARINA-1
Description: ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH)
Study NCT05495243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isotonic saline (0.9%)
Study NCT06785090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone phosphate 0.1%
Description: steroid, standard postoperative care regimen
Study NCT06785090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone phosphate 0.1%
Description: steroid, standard postoperative care regimen
Study NCT06790043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-selected visual art in hospital room
Description: Patient-selected visual art placed in patient's antepartum hospital room
Study NCT06790043 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Patient will receive routine care, and will not select, nor have, visual art in their antepartum hospital room.
Study NCT06789055 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cold Spray
Description: Before the capillary blood glucose measurement, cold spray will be applied to the measurement site from a distance of 30 cm for 10 seconds. Following this, the area will be cleansed with an antimicrobial swab for 10 seconds using a circular motion, starting from the center and moving outward. Subsequently, the fingertip will be punctured with a lancet to obtain a blood sample. The first drop of blood will be wiped away with cotton, and the glucose measurement will be performed using the subsequent drop utilizing the Standard GlucoNavii GDH device. The patient will then be asked to assess their pain during the procedure using the Visual Analog Scale (VAS) for pain evaluation.
Study NCT06789055 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Before the capillary blood glucose measurement, placebo will be applied to the measurement site from a distance of 30 cm for 10 seconds. Following this, the area will be cleansed with an antimicrobial swab for 10 seconds using a circular motion, starting from the center and moving outward. Subsequently, the fingertip will be punctured with a lancet to obtain a blood sample. The first drop of blood will be wiped away with cotton, and the glucose measurement will be performed using the subsequent drop utilizing the Standard GlucoNavii GDH device. The patient will then be asked to assess their pain during the procedure using the Visual Analog Scale (VAS) for pain evaluation.
Study NCT05766657 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Microbiome-targeted diet
Description: The gut microbiota (on stool) and metabolic profile (on stool and urine) will be analyzed at time 0, and the dietary plan will contain specific directions aimed at restoring a proper metagenomic and metabolomic profile of the microbiota.
Study NCT05766657 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Usual care diet
Description: Subjects on the control group will receive general dietetic advice for Obesity or T1D
Study NCT05378035 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Tests
Description: Eligible subjects will receive additional blood tests for determination of DOAC levels and pharmacogenomic studies. Participants shall undergo DOAC level testing at peak, trough, 24, and 48 hours after discontinuation of DOAC for elective medical procedures. We shall also record their baseline demographics, clinical assessments, medical comorbidities, blood parameters, and concurrent medications. We shall minimize the blood taking by combining DOAC levels and blood tests essential for routine medical consultation and pre-procedural workup. Blood taking will only be performed by clinicians or phlebotomists who are experienced in the procedure.
Study NCT04903522 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baroque music listening
Description: Patients will listen to a 30-minute musical path of baroque pieces. Before and after this, anxiety, depression and consciousness fluidity will be evaluated thanks to different questionnaires
Study NCT05435495 — intervention group
Intervention type: PROCEDURE
Intervention: Single-photon emission computed tomography
Description: Imaging procedure
Study NCT05435495 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Blood draw for future research tests (45-60 mL).
Study NCT05435495 — intervention group
Intervention type: PROCEDURE
Intervention: Tumor Biopsy
Description: Guided biopsy of lesion
Study NCT05614024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real fNIRS Neurofeedback
Description: Participants will be instructed to use real-time fNIRS neurofeedback to non-invasively regulate neural activation associated with symptoms in individuals with bulimia nervosa. During the training, participants will view images on a computer screen, listen to sounds, and consume a shake.
Study NCT05614024 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham-Control fNIRS Neurofeedback
Description: Participants will be instructed to use sham real-time fNIRS neurofeedback to non-invasively regulate neural activation associated with symptoms in individuals with bulimia nervosa. During the training, participants will view images on a computer screen, listen to sounds, and consume a shake.
Study NCT04952753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIS793
Description: Investigational drug NIS793 will be administered intravenously (IV) at the dose and schedule determined in the safety run-in part.
Study NCT04952753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered IV
Study NCT04952753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab will be administered IV
Study NCT04952753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified FOLFOX6
Description: 5-fluorouracil \[continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and oxaliplatin \[administered IV\]
Study NCT04952753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modified FOLFOX6
Description: 5-fluorouracil \[continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and oxaliplatin \[administered IV\]
Study NCT04952753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: 5-fluorouracil \[continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and irinotecan \[administered IV\]
Study NCT04952753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: 5-fluorouracil \[continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and irinotecan \[administered IV\]
Study NCT04952753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Investigational drug tislelizumab will be administered intravenously (IV).
Study NCT06229418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DFR AED Pilot Program
Description: Integrate AED drone delivery into an existing FAA-approved drone-as-first-responder programs
Study NCT04757519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DPP-GLB Standard
Description: The intervention is based upon the 2017 version of the University of Pittsburgh DPP Group Lifestyle Balance Program (DPP-GLB). Participants will receive the DPP-GLB intervention once per week for 12 weeks, then twice monthly for 12 weeks (18 sessions total). The program includes hour-long group-based sessions and supportive materials including a weekly food diary and FitBit/pedometer.
Study NCT04757519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DPP-GLB Enhanced
Description: The intervention is based upon the 2017 version of the University of Pittsburgh DPP Group Lifestyle Balance Program (DPP-GLB). Participants will receive the DPP-GLB intervention once per week for 12 weeks, then twice monthly for 12 weeks (18 sessions total). The program includes hour-long group-based sessions and supportive materials including a weekly food diary and FitBit/pedometer. Intervention week 4, weight loss non-responders defined as weight loss less than 1% receive weekly telephone intervention, using motivational interviewing techniques to provide social support, assess barriers, resolve ambivalence, and support the participant in developing personal strategies. Additionally, this intervention includes weekly phone calls using motivational interviewing techniques to provide social support, assess barriers, resolve ambivalence, and support the participant in developing personal strategies. Links to relevant videos may also be provided.
Study NCT05619900 — intervention group
Intervention type: OTHER
Intervention: There is no intervention
Description: This is an observational study. There is no intervention. The purpose of the project is to create a database of patients diagnosed either prenatally or after birth with a lysosomal storage disease. The database will be utilized to assess patient outcomes, build on existing clinical management, improve medical decision making, and improve quality of care.
Study NCT05417100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: methadone 0.2 mg/kg IV.
Study NCT05906511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol 5 MG
Description: Dronabinol 5 mg
Study NCT05906511 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dronabinol 10 MG
Description: Dronabinol 10mg
Study NCT05906511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2mg Purified THC in an ethanolic solution
Description: 2mg Purified THC in an ethanolic solution
Study NCT05906511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4mg Purified THC in an ethanolic solution
Description: 4mg Purified THC in an ethanolic solution
Study NCT05906511 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo and/or vaporized saline
Study NCT04859946 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo stem cell transplant
Study NCT04859946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV
Study NCT04859946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT04859946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT04859946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Given PO
Study NCT04859946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study NCT04859946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV
Study NCT05771428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-552
Description: Oral Capsule
Study NCT05919160 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBC (Diagnostic Biochips) Deep Array microelectrode; Intan Electrophysiology recording system; Matlab response recording to behavioral task
Description: Devices listed are components of a single intervention that includes: Record neuronal activity (Intan) from electrodes (DBC), record and analyze patient responses (Matlab)
Study NCT05748171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin
Description: Inotuzumab ozogamicin (BESPONSA™) is a CD22 targeted antibody drug conjugate (ADC) approved in several countries for the treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). The approved starting dose is 1.8mg/m2/cycle.
Study NCT05748171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALLR3
Description: The ALLR3 chemotherapy regimen (vincristine, mitoxantrone, dexamethasone, and PEG-asparaginase \[or erwinia-asparaginase in the event of an allergic reaction to PEG-asparaginase\]) has been adopted by pediatric oncology groups as treatment for pediatric relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL)
Study NCT05771428 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABBV-552
Description: Oral Capsule
Study NCT05519696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Participants receiving the intervention will complete a 10-week group program. Group sessions meet once per week for 2 hours and include three components - discussion-based health promotion initiative, team-based physical activity games/activities, and team-based goal-setting and behavioral skills training. The health promotion initiative uses cultural targeting and includes a focus on cultural topics related to collectivism. Participants receive FitBits to track their physical activity and through the FitBit mobile app are connected to their group members to encourage communication and social support.
Study NCT05519696 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison
Description: Participants receiving the comparison program will complete a 10-week group program. Group sessions meet once per week for 2 hours and include three components - discussion-based health promotion initiative, group walking program, and individual-based goal-setting and behavioral skills training. The health promotion initiative uses cultural targeting only (and no focus on collectivism). Participants receive FitBits to track their physical activity, but are not connected to their group members on the mobile app.
Study NCT05218213 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Assessment of brain activity with fNIRS and behavioural assessments (motor, motor-cognitive and cognitive) during three complex walking conditions.~1. Dual-task walking with the auditory stroop task.~2. Navigational walking - a course consisting of a distribution of 45 and 90 degrees turns to the left and right~3. Navigational and dual-task walking (condition 1 and 2 together)
Study NCT05220657 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Maximal incremental exercise test
Description: Gas exchanges are measured during all the test on ergocycle until oxygen consumption reach its maximum value
Study NCT04815096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)
Description: \[18F\]F-AraG is a radiolabeled high affinity substrate for deoxyguanosine kinase (dGK) and a low affinity substrate for deoxycytidine kinase (dCK), which are over-expressed in activated T cells.
Study NCT04515836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is a chemotherapy drug (packaged as a pill) that can be taken by mouth, twice daily.
Study NCT04701307 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Given IV